Management of peripheral vertigo with antihistamines: New options on the horizon.

Abstract

Vertigo is associated with a wide range of vestibular pathologies. It increasingly affects the elderly, with a high cost to society. Solutions include vestibular suppressants and vestibular rehabilitation, which form the mainstay of therapy. Antihistamines represent the largest class of agents used to combat vestibular vertigo symptoms. Agents targeting the H1 and H3 receptors have been in clinical use for several decades as single agents. Nonetheless, effective management of vertigo proves elusive as many treatments largely address only associated symptoms, and with questionable efficacy. Additionally, the primary and limiting side effect of sedation is counterproductive to normal functioning and the natural recovery process occurring via central compensation. To address these issues, the timing of administration of betahistine, the mainstay H3 antihistamine, can be fine-tuned, while bioavailability is also being improved. Other approaches include antihistamine combination studies, devices, physical therapy and behavioural interventions. Recently demonstrated expression of H4 receptors in the peripheral vestibular system represents a new potential drug target for treating vestibular disorders. A number of novel selective H4 antagonists are active in vestibular models in vivo. The preclinical potential of SENS-111 (Seliforant), an oral first-in-class selective H4 antagonist is the only such molecule to date to be translated into the clinical setting. With an excellent safety profile and notable absence of sedation, encouraging outcomes in an induced vertigo model in healthy volunteers have led to ongoing clinical studies in acute unilateral vestibulopathy, with the hope that H4 antagonists will offer new effective therapeutic options to patients suffering from vertigo.

• Authors: Jonas Dyhrfjeld-Johnsen, Pierre Attali
• Journal: British journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 85 Issue 10 Pg. 2255-2263 (10 2019) ISSN: 1365-2125 [Electronic] England
• PMID: 31269270 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2019 The British Pharmacological Society.

Chemical References

• Azetidines
• Histamine Agonists
• Histamine Antagonists
• Pyrimidines
• Receptors, Histamine H4
• seliforant
• Betahistine

Topics

• Aged
• Animals
• Azetidines (administration & dosage, adverse effects, pharmacology)
• Betahistine (administration & dosage, pharmacology)
• Histamine Agonists (administration & dosage, pharmacology)
• Histamine Antagonists (administration & dosage, adverse effects, pharmacology)
• Humans
• Pyrimidines (administration & dosage, adverse effects, pharmacology)
• Receptors, Histamine H4 (antagonists & inhibitors, metabolism)
• Vertigo (drug therapy, physiopathology)